Compare GHRS & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GHRS | MFIC |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | GHRS | MFIC |
|---|---|---|
| Price | $21.34 | $11.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | ★ $41.38 | $11.25 |
| AVG Volume (30 Days) | 255.6K | ★ 712.5K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.52 | $9.48 |
| 52 Week High | $24.66 | $13.51 |
| Indicator | GHRS | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 40.84 |
| Support Level | $12.29 | $10.92 |
| Resistance Level | $24.66 | $11.81 |
| Average True Range (ATR) | 1.26 | 0.32 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 67.11 | 9.35 |
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.